Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis

References

• Global tuberculosis report 2017. Geneva: World Health Organization; [cited 2018 Jun 21]. Available from: http://www.who.int/tb/areas-of-work/drug-resistant-tb/MDR_TB_2017.pdf?ua=1
   Google Scholar
• Definitions and reporting framework for tuberculosis-2013 revision. Geneva: World Health Organization; [updated 2014; cited 2018 June 21]. Available from: http://apps.who.int/iris/bitstream/handle/10665/79199/9789?sequence=1
   Google Scholar
• Kohanski MA, DePristo MA, Collins JJ. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell. 2010;37:311–320.
   PubMed Web of Science ®Google Scholar
• Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13:1057–1098.
   PubMed Web of Science ®Google Scholar
• Viswanathan VK. Off-label abuse of antibiotics by bacteria. Gut Microbes. 2014;5:3–4.
   PubMed Web of Science ®Google Scholar
• Garcia-Contreras L, Muttil P, Fallon JK, et al. Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs. Antimicrob Agents Chemother. 2012;56:2612–2618.
   PubMed Web of Science ®Google Scholar
• Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49:1602308.
   PubMed Web of Science ®Google Scholar
• Wood GC, Swanson JM. Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia. Drugs. 2007;67:903–914.
   PubMed Web of Science ®Google Scholar
• Muttil P, Wang C, Hickey AJ. Inhaled drug delivery for tuberculosis therapy. Pharm Res. 2009;26:2401–2416.
   PubMed Web of Science ®Google Scholar
• Daniher DI, Zhu J. Dry powder platform for pulmonary drug delivery. Particuology. 2008;6:225–238.
   Web of Science ®Google Scholar
• Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Dev: Evidence Res. 2015;8:131–139.
   Web of Science ®Google Scholar
• Claus S, Weiler C, Schiewe J, et al. How can we bring high drug doses to the lung? Eur J Pharm Biopharm. 2014;86:1–6.
   PubMed Web of Science ®Google Scholar
• Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmacol Ther. 2003;16:79–95.
   PubMed Web of Science ®Google Scholar
• Hickey AJ, Mansour HM, Telko MJ, et al. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics. J Pharm Sci. 2007;96:1302–1319.
   PubMed Web of Science ®Google Scholar
• Hira D, Okuda T, Kito D, et al. Inhalation performance of physically mixed dry powders evaluated with a simple simulator for human inspiratory flow patterns. Pharm Res. 2010;27:2131–2140.
   PubMed Web of Science ®Google Scholar
• Steckel H, Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. Int J Pharm. 2004;270:297–306.
   PubMed Web of Science ®Google Scholar
• Brunaugh AD, Smyth HD. Formulation techniques for high dose dry powders. Int J Pharm. 2018;547:489–498.
   PubMedGoogle Scholar
• Healy AM, Amaro MI, Paluch KJ, et al. Dry powders for oral inhalation free of lactose carrier particles. Adv Drug Deliv Rev. 2014;75:32–52.
   PubMed Web of Science ®Google Scholar
• Momin MAM, Sinha S, Tucker IG, et al. Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis. Int J Pharm. 2017;528:107–117.
   PubMed Web of Science ®Google Scholar
• Auclair B, Nix DE, Adam RD, et al. Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. Antimicrob Agents Chemother. 2001;45:810–814.
   PubMed Web of Science ®Google Scholar
• Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008;12:128–138.
   PubMed Web of Science ®Google Scholar
• Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2003;47:653–657.
   PubMed Web of Science ®Google Scholar
• Burman
   Google Scholar
  WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006;174:331–338.
   PubMed Web of Science ®Google Scholar
• Fattorini L, Tan D, Iona E, et al. Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. Antimicrob Agents Chemother. 2003;47:360–362.
   PubMed Web of Science ®Google Scholar
• Momin
   Google Scholar
  MAM, Tucker IG, Doyle C, et al. Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections. Int J Pharm. 2018;541:26–36.
   PubMed Web of Science ®Google Scholar
• Pilcer G, De Bueger V, Traina K, et al. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis. Int J Pharm. 2013;451:112–120.
   PubMedGoogle Scholar
• Zhou QT, Gengenbach T, Denman JA, et al. Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection. AAPS J. 2014;16:37–47.
   PubMed Web of Science ®Google Scholar
• Zhou QT, Loh ZH, Yu J, et al. how much surface coating of hydrophobic azithromycin is sufficient to prevent moisture-induced decrease in aerosolisation of hygroscopic amorphous colistin powder? AAPS J. 2016;18:1213–1224.
   PubMed Web of Science ®Google Scholar
• Pilcer G, Vanderbist F, Amighi K. Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties. J Pharm Sci. 2009;98:1463–1475.
   PubMed Web of Science ®Google Scholar
• Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; [cited 2018 June 25]. Available from: http://apps.who.int/iris/bitstream/handle/10665/130918/9789241548809_eng.pdf?sequence=1
   Google Scholar
• Donald PR, McIlleron H. Antituberculosis drugs. In: Schaaf H, Zumla A, editors. Tuberculosis: a comprehensive clinical reference. London (UK): Saunders Elsevier; 2009. p. 608–617.
   Google Scholar
• Liu Y, Sun C, Hao Y, et al. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles. J Pharm Pharm Sci. 2010;13:589–606.
   PubMed Web of Science ®Google Scholar
• Momin MAM, Tucker IG, Doyle CS, et al. Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug. Int J Pharm. 2018;543:318–327.
   PubMed Web of Science ®Google Scholar
• Seville PC, Learoyd TP, Li HY, et al. Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol. 2007;178:40–50.
   Web of Science ®Google Scholar
• Kim EHJ, Dong Chen X, Pearce D. On the mechanisms of surface formation and the surface compositions of industrial milk powders. Drying Technol. 2003;21:265–278.
   Web of Science ®Google Scholar
• Mangal S, Meiser F, Tan G, et al. Relationship between surface concentration of L-leucine and bulk powder properties in spray dried formulations. Eur J Pharm Biopharm. 2015;94:160–169.
   PubMed Web of Science ®Google Scholar
• Sou T, Kaminskas LM, Nguyen TH, et al. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. Eur J Pharm Biopharm. 2013;83:234–243.
   PubMed Web of Science ®Google Scholar
• Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25:999–1022.
   PubMed Web of Science ®Google Scholar
• Chan JG, Tyne AS, Pang A, et al. A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. Pharm Res. 2014;31:1239–1253.
   PubMed Web of Science ®Google Scholar
• Eedara BB, Rangnekar B, Sinha S, et al. Development and characterization of high payload combination dry powders of anti-tubercular drugs for treating pulmonary tuberculosis. Eur J Pharm Sci. 2018;118:216–226.
   PubMed Web of Science ®Google Scholar
• Yu J, Chan HK, Gengenbach T, et al. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders. Eur J Pharm Biopharm. 2017;119:224–234.
   PubMed Web of Science ®Google Scholar
• Stecher PG, Windholz M, Leahy DS, et al. The Merck index. Rahway (NJ): Merck & Co. Inc.; 1968.
   Google Scholar
• Mannava MC, Suresh K, Nangia A. Enhanced bioavailability in the oxalate salt of the anti-tuberculosis drug ethionamide. Cryst Growth Des. 2016;16:1591–1598.
   Web of Science ®Google Scholar
• O'Neil MJ. The Merck index - an encyclopedia of chemicals, drugs, and biologicals. 13th ed. Whitehouse Station (NJ): Merck and Co. Inc; 2001.
   Google Scholar
• Ranjan R, Srivastava A, Bharti R, et al. Preparation and optimization of a dry powder for inhalation of second-line anti-tuberculosis drugs. Int J Pharm. 2018;547:150–157.
   PubMedGoogle Scholar
• Barbosa-Cánovas GV, Ortega-Rivas E, Juliano P, et al. Mixing food powders: physical properties, processing, and functionality. New York (NY): Kluwer Academic; 2005.
   Google Scholar
• Dunber CA, Hickey AJ, Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. Kona. 1998;16:7–45.
   Google Scholar
• Glover W, Chan HK, Eberl S, et al. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int J Pharm. 2008;349:314–322.
   PubMed Web of Science ®Google Scholar
• You Y, Zhao M, Liu G, et al. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method. J Pharm Pharmacol. 2007;59:927–934.
   PubMed Web of Science ®Google Scholar
• Kaialy W, Nokhodchi A. Engineered mannitol ternary additives improve dispersion of lactose-salbutamol sulphate dry powder inhalations. AAPS J. 2013;15:728–743.
   PubMed Web of Science ®Google Scholar
• Hickey AJ. Lung deposition and clearance of pharmaceutical aerosols: what can be learned from inhalation toxicology and industrial hygiene? Aerosol Sci Technol. 1993;18:290–304.
   Web of Science ®Google Scholar
• Price R, Young P, Edge S, et al. The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. Int J Pharm. 2002;246:47–59.
   PubMed Web of Science ®Google Scholar
• Cruz L, Fattal E, Tasso L, et al. Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery. J Control Release. 2011;152:370–375.
   PubMed Web of Science ®Google Scholar
• Lee JH, Chang JH. Lung function in patients with chronic airflow obstruction due to tuberculous destroyed lung. Resp Med. 2003;97:1237–1242.
   PubMed Web of Science ®Google Scholar
• Menezes AM, Hallal PC, Perez-Padilla R, et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Resp J. 2007;30:1180–1185.
   PubMed Web of Science ®Google Scholar
• Allwood BW, Myer L, Bateman ED. A systematic review of the association between pulmonary tuberculosis and the development of chronic airflow obstruction in adults. Respiration. 2013;86:76–85.
   PubMed Web of Science ®Google Scholar
• Hwang YI, Kim JH, Lee CY, et al. The association between airflow obstruction and radiologic change by tuberculosis. J Thor Dis. 2014;6:471.
   PubMed Web of Science ®Google Scholar
• Amaral AF, Coton S, Kato B, et al. Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. Eur Respir J. 2015;46:1104–1112.
   PubMed Web of Science ®Google Scholar
• Mitra R, Pezron I, Li Y, et al. Enhanced pulmonary delivery of insulin by lung lavage fluid and phospholipids. Int J Pharm. 2001;217:25–31.
   PubMed Web of Science ®Google Scholar
• Codrons V, Vanderbist F, Ucakar B, et al. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J Pharm Sci. 2004;93:1241–1252.
   PubMed Web of Science ®Google Scholar